

Supporting Information

Ru(III)-catalyzed C4-H bond cyanoalkylation of 1-naphthylamine derivatives with azobisisobutyronitrile

Lihua Cao, Peisong Wang, Suyan Sun, Fan Yang,* and Yangjie Wu*

*College of Chemistry, Green Catalysis Center, Henan Key Laboratory of Chemical Biology and
Organic Chemistry, Key Laboratory of Applied Chemistry of Henan Universities, Zhengzhou
University, Zhengzhou 450052, PR China*

E-mail: yangf@zzu.edu.cn; wyj@zzu.edu.cn

Table of Contents


| | |
|---|------------|
| 1. General Information | S2 |
| 2. Optimization of Reaction Conditions | S2 |
| 3. Experimental Section | S3 |
| 3.1. Typical procedure for the synthesis of substrate 1-22 | |
| 3.2. Typical procedure for the product 3aa | |
| 3.3. Typical procedure for the product 4a and 5a | |
| 4. Characterization Data of the Products | S5 |
| 5. The Single Crystal X-ray Diffraction Study of 3aa | S18 |
| 6. Copies of ^1H, ^{13}C NMR and HRMS Spectra for the Products | S20 |
| 7. HRMS (ESI$^+$) m/z [M+H$^+$] calcd for the Products | S52 |
| 8. Reference | S68 |

1. General Information

¹H NMR and ¹³C NMR spectra were recorded on a Bruker DPX-400 spectrometer with CDCl₃ as the solvent and TMS as an internal standard. Melting points were measured using a WC-1 microscopic apparatus and are uncorrected. High resolution mass spectra were ensured on an Agilent Technologies 1290-6540 UHPLC/Accurate-Mass Quadrupole Time-of-Flight LC/MS. All solvents were used with further purification. Dichloromethane, ethyl acetate, and hexane were used for column chromatography. The commercials were obtained from commercial sources and used as-received without further purification unless otherwise noted.

2. Optimization of Reaction Conditions


Table S1. Optimization of Catalyst^a



| Entry | Catalyst | Base | Oxidant | Yield(%) ^b |
|-------|---|--------|--|-----------------------|
| 1 | CuSO ₄ ·H ₂ O | PivONa | K ₂ S ₂ O ₈ | 36 |
| 2 | Cu(OAc) ₂ ·H ₂ O | PivONa | K ₂ S ₂ O ₈ | 26 |
| 3 | Cu(acac) ₂ | PivONa | K ₂ S ₂ O ₈ | 27 |
| 4 | Cu(OTf) ₂ | PivONa | K ₂ S ₂ O ₈ | 22 |
| 5 | CuBr ₂ | PivONa | K ₂ S ₂ O ₈ | 10 |
| 6 | AgOAc | PivONa | K ₂ S ₂ O ₈ | 24 |
| 7 | Fe(acac) ₃ | PivONa | K ₂ S ₂ O ₈ | 25 |
| 9 | FeCl ₃ ·6H ₂ O | PivONa | K ₂ S ₂ O ₈ | 18 |
| 10 | FeCl ₂ ·4H ₂ O | PivONa | K ₂ S ₂ O ₈ | 23 |
| 11 | Co(acac) ₃ | PivONa | K ₂ S ₂ O ₈ | 23 |
| 12 | Ni(OAc) ₂ ·4H ₂ O | PivONa | K ₂ S ₂ O ₈ | 18 |
| 13 | NiCl ₂ ·6H ₂ O | PivONa | K ₂ S ₂ O ₈ | 18 |
| 14 | PdCl ₂ | PivONa | K ₂ S ₂ O ₈ | 24 |
| 15 | Pd(OAc) ₂ | PivONa | K ₂ S ₂ O ₈ | 28 |
| 16 | Ru(pph ₃) ₃ Cl ₂ | PivONa | K ₂ S ₂ O ₈ | 48 |
| 17 | Ru(bpy) ₃ PF ₆ | PivONa | K ₂ S ₂ O ₈ | 34 |
| 18 | Ru(bpy) ₃ Cl ₃ ·6H ₂ O | PivONa | K ₂ S ₂ O ₈ | 32 |
| 19 | [RuCl ₂ (p-cymene) ₂] ₂ | PivONa | K ₂ S ₂ O ₈ | 51 |
| 20 | RuCl ₃ ·H ₂ O | PivONa | K ₂ S ₂ O ₈ | 55 |
| 21 | RuCl ₃ ·H ₂ O | PivONa | - | 68 |

^a Reaction conditions: **1a** (0.2 mmol), **2a** (2.0 equiv), catalysts (10 mol%), base (0.4 mmol), oxidant (0.2 mmol), solvent (2 mL) at 80 °C under O₂ for 12 h. ^b Isolated yield.

Table S2. Optimization of Base and Additive ^a




| Entry | Catalyst | Base | Addition | Solvent | Yield(%) ^b |
|-----------------|-------------------------------------|--------------------------------|------------------|--------------------|-----------------------|
| 1 | RuCl ₃ ·H ₂ O | NaOAc | - | CH ₃ CN | 61 |
| 2 | RuCl ₃ ·H ₂ O | KOAc | - | CH ₃ CN | 63 |
| 3 | RuCl ₃ ·H ₂ O | KHCO ₃ | - | CH ₃ CN | 54 |
| 4 | RuCl ₃ ·H ₂ O | KCO ₃ | - | CH ₃ CN | 62 |
| 5 | RuCl ₃ ·H ₂ O | tBuOK | - | CH ₃ CN | 44 |
| 6 | RuCl ₃ ·H ₂ O | KI | - | CH ₃ CN | NR |
| 7 | RuCl ₃ ·H ₂ O | NH ₄ OAc | - | CH ₃ CN | 57 |
| 8 | RuCl ₃ ·H ₂ O | K ₃ PO ₄ | - | CH ₃ CN | 55 |
| 9 | RuCl ₃ ·H ₂ O | PivOH | - | CH ₃ CN | 42 |
| 10 | RuCl ₃ ·H ₂ O | NaCl | - | CH ₃ CN | 49 |
| 11 | RuCl ₃ ·H ₂ O | PivONa | - | THF | <10 |
| 12 | RuCl ₃ ·H ₂ O | PivONa | - | 1,4-Dioxane | NR |
| 13 | RuCl ₃ ·H ₂ O | PivONa | - | DCE | NR |
| 14 | RuCl ₃ ·H ₂ O | PivONa | - | Acetone | NR |
| 15 | RuCl ₃ ·H ₂ O | PivONa | - | Dioxane | NR |
| 16 | RuCl ₃ ·H ₂ O | PivONa | PPh ₃ | CH ₃ CN | 61 |
| 17 | RuCl ₃ ·H ₂ O | PivONa | diMe-phen | CH ₃ CN | 69 |
| 18 | RuCl ₃ ·H ₂ O | PivONa | TBAB | CH ₃ CN | 58 |
| 19 | RuCl ₃ ·H ₂ O | PivONa | x-phos | CH ₃ CN | 60 |
| 20 | RuCl ₃ ·H ₂ O | PivONa | 1,10-phen | CH ₃ CN | 67 |
| 21 | RuCl ₃ ·H ₂ O | PivONa | bpy | CH ₃ CN | 72 |
| 22 ^c | RuCl ₃ ·H ₂ O | PivONa | bpy | CH ₃ CN | 80 |

^a Reaction conditions: **1a** (0.2 mmol), **2a** (2.0 equiv), catalysts (10 mol%), base (0.4 mmol), addition (20 mol%), solvent (2 mL) at 80 °C under O₂ for 12 h. ^b Isolated yield. ^c **2a** (0.8 mmol); 1,10-phen = 1,10-phenanthroline, bpy = 2, 2'-bipyridine, diMe-phen = 4,7-dimethyl-1,10-phenanthroline

3. Experimental Section

3.1. Typical procedure for the synthesis of substrate 1-22




A 100 mL two-necked round-bottom flask was equipped with a magnetic stir bar and charged with 1-naphthylamine (20 mmol, 2.86 g), picolinic acid (1.1 equiv., 2.70 g), N,N-dimethyl-4-aminopyridine (DMAP, 0.1 equiv., 0.244 g) in 30 mL anhydrous CH_2Cl_2 at 0 °C. After DCC (4.54 g, 1.1 equiv.) in CH_2Cl_2 (20 mL) was added dropwise to the solution, the reaction was then warmed to room temperature, stirred for 12 h and quenched with water (30 mL). The reaction mixture was extracted with CH_2Cl_2 (3×20 mL), and the combined organic solvent was dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography (hexane/ethyl acetate = 3:1) (V/V) to afford the pure product **1** as a white solid (4.42 g, 89%).

All amides **2-22** were prepared from the corresponding 1-naphthylamine and 2-picolinic acid derivatives according to the reported procedure¹.

3.2. Typical procedure for the product **3aa**

A Schlenk tube was equipped with a magnetic stir bar and charged with N-(naphthalen-1-yl)picolinamide **1a** (0.2 mmol, 49.6 mg), **2a** (0.8 mmol, 131 mg), RuCl₃·H₂O (0.02 mmol, 5 mg), PivONa·H₂O (0.4 mmol, 56.8 mg), bpy (0.04 mmol, 6.2 mg), MeCN 2.0 mL. The resulting mixture was sealed under O₂, heated at 80 °C for 12 h, and cooled to room temperature. Upon completion, CH₂Cl₂ (30 mL) was added to the reaction system, and the resulting mixture was filtered through a pad of Celite. After the organic material was concentrated in vacuum, the product was purified by column chromatography on silica gel (100-200 mesh) using hexane/EtOAc as an eluent (5:1-3:1, V/V) to afford the pure product **3aa**.


3.3. Typical procedure for the product **4a** and **5a**



A mixture of **3aa** (66.2 mg, 0.2 mmol) and HCl (1 mL) was heated in ethanol (2 mL) for 12 h at 100 °C. After the mixture was cooled to room temperature and diluted with water (3.0 mL). The saturated NaHCO₃ solution was then added until the pH value was about 7. The mixture was then extracted with CH₂Cl₂ and dried over anhydrous Na₂SO₄. After the organic material was concentrated in vacuum, the product was purified by column chromatography on silica gel (100-200 mesh) using hexane/EtOAc as an eluent (2:1, V/V) to afford the pure product **4a**.

A mixture of **3aa** (66.2 mg, 0.2 mmol) and NaOH (160 mg, 4 mmol, 20 equiv) was heated in ethanol (2 mL) for 12 h at 90 °C. After the mixture was cooled to room temperature and diluted with water (3.0 mL). The mixture was then extracted with CH₂Cl₂ and dried over anhydrous Na₂SO₄. After the organic material was concentrated in vacuum, the product was purified by column chromatography on silica gel (100-200 mesh) using hexane/EtOAc as an eluent (2:1, V/V) to afford the pure product **5a**.


4. Characterization Data of the Products



3aa

N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)picolinamide


(3aa): pale yellow solid (52.7 mg, 80%), mp 124-126 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.60 (s, 1H), 8.71-8.70 (m, 1H), 8.35 (d, *J* = 7.80 Hz, 1H), 8.26 (d, *J* = 8.36 Hz, 1H), 8.19-8.17 (m, 1H), 8.06 (d, *J* = 8.22 Hz, 1H), 7.97-7.93 (m, 1H), 7.64-7.51 (m, 4H), 1.85 (s, 6H); ¹³C NMR (100 MHz, CDCl₃), δ 162.4, 149.9, 148.2, 147.7, 137.8, 128.8, 128.7, 128.0, 127.0, 126.6, 126.1, 122.9, 122.6, 121.1, 120.9, 119.0, 114.5, 72.4, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₀H₁₇N₃O₂: 332.1394, Found: 332.1394.



3ba

N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)-6-methylpicolinamide


(3ba): yellow solid (45.5 mg, 66%), mp 123-125 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.66 (s, 1H), 8.24 (d, *J*=8.38 Hz, 1H), 8.19-8.15 (m, 2H), 8.04 (d, *J* = 8.36 Hz, 1H), 7.82 (t, *J* = 7.72 Hz, 1H), 7.64-7.60 (m, 1H), 7.58-7.54 (m, 2H), 7.37 (d, *J* = 7.68 Hz, 1H), 2.70 (s, 3H); ¹³C NMR (100MHz, CDCl₃), δ 162.6, 157.3, 149.2, 147.6, 137.9, 128.9, 128.8, 128.1, 126.9, 126.3, 126.1, 122.9, 121.1, 121.0, 119.6, 119.1, 114.6, 72.3, 27.5, 24.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₁H₁₉N₃O₂: 346.1550, Found: 346.1551.



3ca

N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)-3-methylpicolinamide


(3ca): white solid (48.2 mg, 69%), mp 97-99 °C; ¹H NMR (400MHz, CDCl₃) δ 10.79 (s, 1H), 8.55-8.54 (m, 1H), 8.20-8.16 (m, 2H), 8.05 (d, *J* = 8.04 Hz, 1H), 7.69-7.67 (m, 1H) 7.62-7.53 (m, 3H), 7.41 (dd, *J*₁ = 7.72 Hz, *J*₂ = 4.60 Hz, 1H), 2.85 (s, 3H), 1.84 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 164.0, 147.5, 146.8, 145.6, 141.4, 136.4, 129.2, 128.9, 128.3, 126.8, 126.2, 126.0, 122.8, 121.2, 121.1, 119.2, 114.6, 72.4, 27.5, 20.7; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₁H₁₉N₃O₂: 346.1550, Found: 346.1550.



3da

N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)-4-methoxypicolinamide


(3da): white solid (49.7 mg, 68%), mp 117-119 °C; ¹H NMR (400MHz, CDCl₃) δ 10.66 (s, 1H), 8.49 (d, *J* = 5.64 Hz, 1H), 8.26 (d, *J* = 8.36 Hz, 1H), 8.19-8.17 (m, 1H), 8.05 (d, *J* = 8.24 Hz, 1H), 7.88 (d, *J* = 2.52 Hz, 1H), 7.63-7.54 (m, 3H), 7.01 (dd, *J*₁ = 5.64 Hz, *J*₂ = 2.60 Hz, 1H), 3.96 (s, 3H), 1.85 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 167.3, 162.4, 152.0, 149.3, 147.6, 128.8, 127.9, 126.9, 126.1, 122.9, 121.1, 121.0, 118.9, 114.5, 113.4, 107.7, 72.3, 55.7, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₁H₁₉N₃O₃: 362.1499, Found: 362.1499.



3ea

N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)-6-fluoropicolinamide


(3ea): white solid (45.5 mg, 65%); mp 123-125 °C ¹H NMR (400MHz, CDCl₃) δ 10.07 (s, 1H), 8.25 (dd, *J*₁ = 7.36 Hz, *J*₂ = 1.68 Hz, 1H), 8.19-8.16 (m, 2H), 8.09-8.00 (m, 2H), 7.65-7.54 (m, 3H), 7.19 (dd, *J*₁ = 8.16 Hz, *J*₂ = 2.00 Hz, 1H), 1.86 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 162.1 (d, *J*_{C-F} = 243.32 Hz), 161.1, 148.5 (d, *J*_{C-F} = 10.66 Hz), 148.1, 142.9 (d, *J*_{C-F} = 7.56 Hz), 128.7, 128.2, 128.1, 127.1, 126.2, 122.9, 121.0, 120.9, 120.3 (d, *J*_{C-F} = 3.69 Hz), 119.7, 114.2, 113.2 (d, *J*_{C-F} = 35.57 Hz), 72.3, 27.5; ¹⁹F NMR (376MHz, CDCl₃), δ -76.1 (s, 1F); HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₀H₁₆FN₃O₂: 350.1299, Found: 350.1299.



3fa

N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)-5-fluoropicolinamide


(3fa): white solid (55.1 mg, 79%), mp 128-130 °C; ¹H NMR (400MHz, CDCl₃) δ 10.33 (s, 1H), 8.54 (d, *J* = 2.72 Hz, 1H), 8.39 (dd, *J*₁ = 8.68 Hz, *J*₂ = 4.60 Hz, 1H), 8.22-8.17 (m, 2H), 8.01 (d, *J* = 8.12 Hz, 1H), 7.66-7.54 (m, 4H), 1.85 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 161.3 (d, *J*_{C-F} = 259,79 Hz), 161.4, 147.8, 146.3 (d, *J*_{C-F} = 3.74 Hz), 136.7 (d, *J*_{C-F} = 25.39 Hz), 128.7, 128.5, 128.0, 127.0, 126.1, 124.4 (d, *J*_{C-F} = 8.75 Hz), 124.3 (d, *J*_{C-F} = 21.40 Hz), 122.9, 121.0, 120.8, 119.3, 114.4, 72.3, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₀H₁₆FN₃O₂: 350.1299, Found: 350.1297.



3ga

6-chloro-N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)picolinamide


(3ga): white solid (50.9 mg, 70%), mp 94-96 °C; ¹H NMR (400MHz, CDCl₃) δ 10.19 (s, 1H), 8.29-8.27 (m, 1H), 8.19-8.17 (m, 1H), 8.15 (d, *J* = 8.32 Hz, 1H), 8.01 (d, *J* = 8.32 Hz, 1H), 7.91 (t, *J* = 7.80 Hz, 1H), 7.65-7.61 (m, 1H), 7.59-7.54 (m, 3H), 1.86 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 161.1, 150.4, 150.1, 148.1, 140.4, 128.7, 128.3, 128.2, 127.4, 127.1, 126.2, 122.9, 121.3, 121.0, 120.9, 119.8, 114.2, 72.3, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₀H₁₆ClN₃O₂: 366.1004, Found: 366.1003.



3ha

5-chloro-N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)picolinamide


(3ha): pale yellow solid (50.4 mg, 69%), mp 117-119 °C; ¹H NMR (400MHz, CDCl₃) δ 10.36 (s, 1H), 8.65 (d, *J* = 2.28 Hz, 1H), 8.31 (d, *J* = 8.40 Hz, 1H), 8.23-8.18 (m, 2H), 8.01 (d, *J* = 8.36 Hz, 1H), 7.93-7.91 (m, 1H), 7.64-7.54 (m, 3H), 1.85 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 161.6, 148.1, 147.9, 147.3, 137.5, 135.5, 128.7, 128.3, 128.0, 127.1, 126.2, 123.6, 123.0, 121.0, 120.8, 119.3, 114.3, 72.3, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₀H₁₆ClN₃O₂: 366.1004, Found: 366.1001.



3ia

4-chloro-N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)picolinamide


(3ia): yellow solid (48.8 mg, 67%), mp 120-122 °C; ¹H NMR (400MHz, CDCl₃) δ 10.46 (s, 1H), 8.59 (d, *J* = 5.24 Hz, 1H), 8.36 (d, *J* = 2.04 Hz, 1H), 8.23 (d, *J* = 8.36 Hz, 1H), 8.19-8.17 (m, 1H), 8.01 (d, *J* = 8.08 Hz, 1H), 7.64-7.52 (m, 4H), 1.85 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 161.2, 151.4, 149.1, 147.9, 146.4, 128.7, 128.3, 127.9, 126.8, 126.2, 123.2, 123.0, 121.0, 120.8, 119.3, 72.3, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₀H₁₆ClN₃O₂: 366.1004, Found: 366.1001.



3ja


3,5-dichloro-N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)picolinamide

(3ja): white solid (50.2 mg, 63%), mp 127-129 °C; ¹H NMR (400MHz, CDCl₃) δ 10.22 (s, 1H), 8.56 (d, *J* = 2.04 Hz, 1H), 8.19-8.16 (m, 2H), 7.96-7.92 (m, 2H), 7.62-7.52 (m, 3H), 1.84 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 160.5, 148.0, 145.2, 143.8, 140.2, 134.7, 133.1, 128.7, 128.2, 128.1, 127.0, 126.2, 123.0, 121.0, 120.8, 119.6, 114.3, 72.3, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₀H₁₅Cl₂N₃O₂: 400.0614, Found: 400.0618.




6-bromo-N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)picolinamide

(3ka): white solid (61.5 mg, 75%), mp 103-105 °C; ¹H NMR (400MHz, CDCl₃) δ 10.17 (s, 1H), 8.32-8.30 (m, 1H), 8.18 (d, *J* = 8.12 Hz, 1H), 8.14 (d, *J* = 8.32 Hz, 1H), 8.00 (d, *J* = 8.36 Hz, 1H), 7.81 (t, *J* = 7.68 Hz, 1H), 7.73-7.70 (m, 1H), 7.65-7.61 (m, 1H), 7.59-7.54 (m, 2H), 1.86 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 161.0, 151.0, 148.2, 140.6, 140.1, 131.2, 128.7, 128.3, 128.2, 127.2, 126.2, 122.9, 121.6, 121.1, 121.0, 119.9, 114.2, 72.3, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₀H₁₆BrN₃O₂: 410.0499, Found: 410.0501.




5-bromo-N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)picolinamide

(3la): white solid (50.2 mg, 62%), mp 103-105 °C; ¹H NMR (400MHz, CDCl₃) δ 10.37 (s, 1H), 8.76 (d, *J* = 1.88 Hz, 1H), 8.26-8.17 (m, 3H), 8.08 (dd, *J*₁ = 8.32 Hz, *J*₂ = 2.20 Hz, 1H), 8.00 (d, *J* = 8.20 Hz, 1H), 7.64-7.54 (m, 3H), 1.85 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 161.7, 149.4, 148.4, 147.9, 140.5, 128.7, 128.4, 128.0, 127.0, 126.2, 124.4, 124.0, 122.9, 121.0, 120.8, 119.3, 114.3, 72.3, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₀H₁₆BrN₃O₂: 410.0499, Found: 410.0499.




4-bromo-N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)picolinamide

(3ma): white solid (56.9 mg, 70%), mp 124-126 °C; ¹H NMR (400MHz, CDCl₃) δ 10.45 (s, 1H), 8.53-8.51 (m, 2H), 8.23 (d, *J* = 8.36 Hz, 1H), 8.19-8.17 (m, 1H), 8.01 (d, *J* = 8.12 Hz, 1H), 7.70 (dd, *J*₁ = 5.16 Hz, *J*₂ = 1.96 Hz, 1H), 7.64-7.55 (m, 3H), 1.86 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 161.1, 151.1, 148.9, 147.9, 135.0, 129.9, 128.7, 128.3, 128.0, 127.0, 126.2, 126.1, 123.0, 121.0, 120.8, 119.3, 114.3, 72.3, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₀H₁₆BrN₃O₂: 410.0499, Found: 410.0498.




3-bromo-N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)picolinamide

(3na): pale yellow solid (48.8 mg, 60%), mp 128-130 °C; ¹H NMR (400MHz, CDCl₃) δ 10.48 (s, 1H), 8.66-8.65 (m, 1H), 8.22 (d, *J* = 8.40 Hz, 1H), 8.19-8.13 (m, 2H), 8.00 (d, *J* = 8.08 Hz, 1H), 7.62-7.53 (m, 3H), 7.37 (dd, *J*₁ = 8.12 Hz, *J*₂ = 4.48 Hz, 1H), 1.85 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 161.5, 147.8, 146.7, 146.6, 144.5, 128.8, 128.6, 128.2, 127.0, 126.9, 126.1, 123.0, 121.0, 120.9, 120.0, 119.5, 114.5, 72.4, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₀H₁₆BrN₃O₂: 409.0499, Found: 410.0495.



N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)isoquinoline-1-carboxamide


(3oa): Yellow liquid (51 mg, 67%); ¹H NMR (400MHz, CDCl₃) δ 10.90 (s, 1H), 9.80-9.77 (m, 1H), 8.62 (d, *J* = 5.48 Hz, 1H), 8.25 (d, *J* = 8.36 Hz, 1H), 8.20-8.18 (m, 1H), 8.11 (d, *J* = 8.16 Hz, 1H), 7.92-7.90 (m, 2H), 7.79-7.71 (m, 2H), 7.64-7.54 (m, 3H), 1.86 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 164.1, 147.8, 147.5, 140.2, 137.7, 130.7, 129.1, 129.0, 128.9, 128.5, 127.9, 127.4, 127.0, 126.9, 126.1, 125.1, 122.9, 121.3, 121.1, 119.5, 114.5, 72.4, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₄H₁₉N₃O₂: 382.1550, Found: 382.1550.



3pa

N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)quinoline-2-carboxamide


(3pa): pale yellow solid (39.8 mg, 55%), mp 175-176 °C; ¹H NMR (400MHz, CDCl₃) δ 10.81 (s, 1H), 8.48-8.41 (m, 2H), 8.30-8.26 (m, 2H), 8.20 (d, *J* = 7.84 Hz, 1H), 8.15 (d, *J* = 8.36 Hz, 1H), 7.95 (d, *J* = 8.16 Hz, 1H), 7.87-7.83 (m, 1H), 7.71-7.64 (m, 2H), 7.61-7.58 (m, 2H), 1.87 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 162.6, 149.7, 147.8, 146.4, 138.0, 130.4, 129.9, 129.6, 128.8, 128.7, 128.3, 128.2, 127.9, 127.0, 126.1, 123.0, 121.1, 121.0, 119.3, 119.0, 118.9, 114.5, 72.3, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₄H₁₉N₃O₂: 382.1550, Found: 382.1546.



3qa

N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)pyrimidine-4-carboxamide


(3qa): yellow solid (35.1 mg, 53%); mp 118-120 °C; ¹H NMR (400MHz, CDCl₃) δ 10.43 (s, 1H), 9.40 (d, *J* = 1.32 Hz, 1H), 9.09 (d, *J* = 5.00 Hz, 1H), 8.29-8.19 (m, 3H), 8.02 (d, *J* = 8.36 Hz, 1H), 7.67-7.55 (m, 3H), 1.86 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 160.6, 159.7, 157.8, 156.4, 148.2, 128.7, 127.9, 127.7, 127.2, 126.3, 123.0, 120.9, 120.6, 119.5, 118.8, 114.1, 72.3, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₁₉H₁₄N₄O₂: 333.1346, Found: 333.1346.



3ra


N-(4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)pyrazine-2-carboxamide

(3ra): pale yellow solid (35 mg, 52%), mp 164-166 °C; ¹H NMR (400MHz, CDCl₃) δ 10.19 (s, 1H), 9.57 (d, *J* = 1.28 Hz, 1H), 8.86 (d, *J* = 2.44 Hz, 1H), 8.68-8.67 (m, 1H), 8.22-8.18 (m, 2H), 8.00 (d, *J* = 8.12 Hz, 1H), 7.64-7.55 (m, 3H), 1.86 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 161.1, 148.1, 147.7, 144.8, 144.5, 142.6, 128.7, 128.0, 127.9, 127.1, 126.3, 123.0, 121.0, 120.7, 119.7, 114.2, 72.3, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₁₉H₁₄N₄O₂: 333.1346, Found: 333.1343.




N-(4-((2-cyanopropan-2-yl)oxy)-8-methylnaphthalen-1-yl)picolinamide

(3ab): white solid (23.2 mg, 33%), mp 125-127 °C; ¹H NMR (400MHz, CDCl₃) δ 10.45 (s, 1H), 8.67-8.65 (m, 1H), 8.36 (d, *J* = 7.80 Hz, 1H), 8.06 (d, *J* = 8.16 Hz, 1H), 7.96-7.12 (m, 2H), 7.54-7.50 (m, 2H), 7.39-7.30 (m, 2H), 2.95 (s, 3H), 1.84 (s, 6H), ¹³C NMR (100MHz, CDCl₃), δ 161.5, 149.0, 147.9, 147.2, 136.6, 131.9, 129.8, 129.2, 128.6, 128.3, 125.4, 124.6, 122.7, 121.7, 120.2, 120.1, 112.9, 72.2, 26.4, 23.9; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₁H₁₉N₃O₂: 346.1550, Found: 346.1548.



N-(4-((2-cyanopropan-2-yl)oxy)-8-methoxynaphthalen-1-yl)picolinamide


(3ac): yellow solid (36.8 mg, 52%), mp 132-134 °C; ¹H NMR (400MHz, CDCl₃) δ 13.14 (s, 1H), 8.94 (d, *J* = 8.68 Hz, 1H), 8.69 (d, *J* = 4.24 Hz, 1H), 8.34 (d, *J* = 7.80 Hz, 1H), 7.92 (m, 1H), 7.76 (d, *J* = 8.48 Hz, 1H), 7.55 (d, *J* = 8.64 Hz, 1H), 7.49-7.46 (m, 1H), 7.43-7.39 (m, 1H), 6.96 (d, *J* = 7.68 Hz, 1H), 4.20 (s, 3H), 1.82 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 162.3, 156.3, 151.1, 148.1, 156.0, 137.6, 131.8, 131.1, 126.1, 125.9, 122.6, 121.2, 117.8, 116.2, 116.1, 115.6, 106.5, 72.6, 56.3, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₁H₁₉N₃O₃: 362.1499, Found: 362.1497.



3ad

N-(4-((2-cyanopropan-2-yl)oxy)-8-phenylnaphthalen-1-yl)picolinamide


(3ad): yellow solid (54.4 mg, 66%), mp 141-143 °C; ¹H NMR (400MHz, CDCl₃) δ 9.44 (s, 1H), 8.24-8.22 (m, 1H), 8.19-8.17 (m, 1H), 8.10 (d, *J* = 8.44 Hz, 1H), 8.06 (d, *J* = 7.80 Hz, 1H), 7.78-7.74 (m, 1H), 7.61 (d, *J* = 8.44 Hz, 1H), 7.54-7.50 (m, 1H), 7.38-7.30 (m, 4H), 7.17-7.14 (m, 2H), 6.99-6.95 (m, 1H), 1.89 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 162.0, 149.7, 148.3, 147.4, 142.6, 137.9, 137.0, 131.2, 130.0, 129.1, 129.0, 128.1, 126.7, 126.5, 125.8, 125.0, 122.7, 122.4, 121.8, 121.1, 114.5, 72.4, 27.6; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₆H₂₁N₃O₂: 408.1701, Found: 408.1707.



3ae

N-(4-((2-cyanopropan-2-yl)oxy)-7-methoxynaphthalen-1-yl)picolinamide


(3ae): pale yellow solid (21.2 mg, 29%), mp 120-122 °C; ¹H NMR (400MHz, CDCl₃) δ 10.36 (s, 1H), 8.68 (d, *J* = 4.20 Hz, 1H), 8.35 (d, *J* = 7.80 Hz, 1H), 8.11-8.07 (m, 2H), 7.97-7.53 (m, 1H), 7.54-7.51 (m, 1H), 7.40 (d, *J* = 8.32 Hz, 1H), 7.28 (d, *J* = 2.32 Hz, 1H), 7.20 (dd, *J*₁ = 9.20 Hz, *J*₂ = 2.40 Hz, 1H), 3.95 (s, 3H), 1.84 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 162.5, 158.6, 150.0, 148.2, 148.1, 137.8, 129.9, 127.5, 126.6, 124.7, 124.0, 122.6, 121.1, 120.8, 118.1, 112.1, 100.5, 72.2, 55.4, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₁H₁₉N₃O₃: 362.1499, Found: 362.1502.



3af

N-(5-bromo-4-((2-cyanopropan-2-yl)oxy)naphthalen-1-yl)picolinamide


(3af): white solid (21.2 mg, 29%), mp 141-143 °C; ¹H NMR (400MHz, CDCl₃) δ 10.47 (s, 1H), 8.70-8.69 (m, 1H), 8.34 (d, *J* = 7.80 Hz, 1H), 8.19 (d, *J* = 8.44 Hz, 1H), 8.06-8.04 (m, 1H), 7.98-7.94 (m, 1H), 7.98-7.94 (m, 1H), 7.89-7.87 (m, 1H), 7.74 (d, *J* = 8.44 Hz, 1H), 7.56-7.53 (m, 1H), 1.86 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 162.6, 149.7, 148.2, 147.6, 137.9, 134.3, 130.8, 129.3, 126.8, 126.7, 122.7, 121.4, 121.3, 121.0, 118.2, 117.0, 73.8, 27.0; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₀H₁₆BrN₃O₂: 410.0499, Found: 410.0501.



3ag

N-(5-((2-cyanopropan-2-yl)oxy)quinolin-8-yl)picolinamide


(3ag): white solid (49.4 mg, 74%), mp 147-149 °C; ¹H NMR (400MHz, CDCl₃) δ 12.15 (s, 1H), 8.99-8.97 (m, 2H), 8.79-8.77 (m, 1H), 8.48-8.46 (m, 1H), 8.35 (d, *J* = 7.80 Hz, 1H), 7.95-7.91 (m, 1H), 7.56 (d, *J* = 8.56 Hz, 1H), 7.53-7.49 (m, 2H), 1.85 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 162.6, 150.4, 149.2, 148.6, 144.9, 139.9, 137.5, 131.2, 131.1, 126.3, 123.5, 122.5, 121.5, 121.0, 116.3, 115.9, 72.6, 27.5; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₁₉H₁₆N₄O₂: 333.1346, Found: 333.1348.



3ah


N-(8-((2-cyanopropan-2-yl)oxy)quinolin-5-yl)picolinamide

(3ah): pale yellow solid (21.9 mg, 33%), mp 135-137 °C; ¹H NMR (400MHz, CDCl₃) δ 10.55 (s, 1H), 9.02-9.00 (m, 1H), 8.71-8.70 (m, 1H), 8.43-8.40 (m, 1H), 8.35 (d, *J* = 7.80 Hz, 1H), 8.26 (d, *J* = 8.40 Hz, 1H), 7.99-7.95 (m, 1H), 7.79 (d, *J* = 8.40 Hz, 1H), 7.58-7.52 (m, 2H), 1.89 (s, 6H); ¹³C NMR (100MHz, CDCl₃), δ 162.6, 150.2, 149.5, 148.2, 148.1, 143.2, 137.9, 130.0, 129.1, 126.9, 123.6, 122.7, 121.5, 121.1, 120.5, 120.0, 73.9, 27.6; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₁₉H₁₆N₄O₂: 333.1346, Found: 333.1349.




N-(4-((1-cyanocyclohexyl)oxy)naphthalen-1-yl)picolinamide

(3ak): pale yellow solid (25.8 mg, 35%), mp 121-123 °C; ¹H NMR (400MHz, CDCl₃) δ 10.57 (s, 1H), 8.71-8.70 (m, 1H), 8.36 (d, *J* = 7.80 Hz, 1H), 8.26-8.22 (m, 2H), 8.05 (d, *J* = 8.12 Hz, 1H), 7.97-7.93 (m, 1H), 7.63-7.52 (m, 4H), 2.37-2.33 (m, 2H), 2.06-2.00 (m, 2H), 1.86-1.83 (m, 2H), 1.70-1.62 (m, 3H), 1.43-1.36 (m, 1H); ¹³C NMR (100MHz, CDCl₃), δ 162.4, 150.0, 148.2, 147.3, 137.8, 128.5, 128.3, 128.1, 126.9, 126.6, 126.0, 122.9, 122.6, 121.0, 120.3, 119.2, 113.9, 35.8, 24.6, 22.4; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₃H₂₁N₃O₂: 372.1707, Found: 372.1710.




N-(4-((2-cyanobutan-2-yl)oxy)naphthalen-1-yl)picolinamide

(3al): pale yellow solid (17.3 mg, 28%), mp 125-127 °C; ¹H NMR (400MHz, CDCl₃) δ 10.59 (s, 1H), 8.71-8.70 (m, 1H), 8.36 (d, *J* = 7.40 Hz, 1H), 8.25 (d, *J* = 8.36 Hz, 1H), 8.20-8.18 (m, 1H), 8.06 (d, *J* = 8.28 Hz, 1H), 7.97-7.93 (m, 1H), 7.63-7.59 (m, 1H), 7.57-7.52 (m, 3H), 2.31-2.21 (m, 1H), 2.17-2.11 (m, 1H), 1.72 (s, 3H), 1.27 (t, *J* = 7.55Hz, 3H); ¹³C NMR (100MHz, CDCl₃), δ 162.4, 150.0, 148.2, 147.6, 137.8, 128.7, 128.5, 128.0, 126.9, 126.6, 126.1, 122.9, 122.6, 121.0, 120.4, 119.1, 114.1, 76.4, 34.2, 24.2, 8.7; HRMS (ESI⁺) m/z [M+H⁺] calcd for C₂₁H₁₉N₃O₂: 346.1550, Found: 346.1554.




2-((4-aminonaphthalen-1-yl)oxy)-2-methylpropanenitrile

(4a): brown liquid (34.4 mg, 76%), ^1H NMR (400MHz, CDCl_3) δ 8.07-8.05 (m, 1H), 7.82-7.80 (m, 1H), 7.51-7.48 (m, 2H), 7.37 (d, $J = 8.12$ Hz, 1H), 6.72 (d, $J = 8.12$ Hz, 1H), 1.76 (s, 6H); ^{13}C NMR (100MHz, CDCl_3), δ 143.2, 139.0, 129.5, 126.0, 125.5, 124.6, 122.8, 121.6, 121.2, 116.9, 109.1, 73.1, 27.4; HRMS (ESI $^+$) m/z [M+H $^+$] calcd for $\text{C}_{14}\text{H}_{14}\text{N}_2\text{O}$: 227.1173, Found: 227.1180.



2-((4-aminonaphthalen-1-yl)oxy)-2-methylpropanamide


(5a): brown solid (40.1 mg, 82%), mp 94-96 °C; ^1H NMR (400MHz, CDCl_3) δ 8.17-8.15 (m, 1H), 7.83-7.80 (m, 1H), 7.51-7.49 (m, 2H), 6.88 (d, $J = 8.08$ Hz, 1H), 6.66 (d, $J = 8.04$ Hz, 1H), 1.57 (s, 6H); ^{13}C NMR (100MHz, CDCl_3), δ 178.3, 143.1, 137.9, 129.4, 125.8, 125.5, 124.8, 123.0, 121.2, 115.9, 109.0, 82.1, 25.0; HRMS (ESI $^+$) m/z [M+H $^+$] calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_2$: 245.1285, Found: 245.1283.



N-(4-((2-cyanopropan-2-yl)oxy)-2-morpholinonaphthalen-1-yl)picolinamide


(6a): brown solid (50.7 mg, 61%), mp 187-189 °C; ^1H NMR (400MHz, CDCl_3) δ 10.17 (s, 1H), 8.73 (d, $J = 4.68$ Hz, 1H), 8.35 (d, $J = 7.76$ Hz, 1H), 8.04 (d, $J = 8.36$ Hz, 1H), 7.98-7.94 (m, 1H), 7.87 (d, $J = 8.36$ Hz, 1H), 7.57-7.49 (m, 3H), 7.45-7.41 (m, 1H), 3.82-3.80 (m, 4H), 3.04-3.02 (m,

4H), 1.84 (s, 6H); ^{13}C NMR (100MHz, CDCl_3), δ 163.6, 150.2, 149.9, 148.3, 144.2, 137.7, 130.7, 127.0, 126.6, 125.9, 124.9, 124.5, 122.8, 122.3, 122.1, 121.3, 108.3, 72.7, 67.4, 51.9, 27.5; HRMS (ESI $^+$) m/z [M+H $^+$] calcd for $\text{C}_{24}\text{H}_{24}\text{N}_4\text{O}_3$: 417.1921, Found: 417.1921.



N-(4-((2-cyanopropan-2-yl)oxy)-8-morpholinonaphthalen-1-yl)picolinamide

(7a): white solid (40.1 mg, 48%), mp 144-146 °C; ^1H NMR (400MHz, CDCl_3) δ 13.79 (s, 1H), 9.10 (d, $J = 8.72$ Hz, 1H), 8.74-8.73 (m, 1H), 8.38 (d, $J = 7.84$ Hz, 1H), 8.02-7.92 (m, 2H), 7.56-7.42 (m, 4H), 4.28-4.22 (m, 2H), 3.86-3.84 (m, 2H), 3.20-3.18 (m, 2H), 3.06-3.00 (m, 2H), 1.83 (s, 6H), ^{13}C NMR (100MHz, CDCl_3), δ 163.1, 151.2, 149.3, 147.9, 146.5, 137.6, 132.0, 130.9, 126.4, 125.7, 123.4, 121.1, 121.0, 119.8, 117.9, 116.6, 115.3, 72.5, 65.6, 54.5, 27.5; HRMS (ESI $^+$) m/z [M+H $^+$] calcd for $\text{C}_{24}\text{H}_{24}\text{N}_4\text{O}_3$: 417.1921, Found: 417.1925.




2-(2,6-di-tert-butyl-4-methylphenoxy)-2-methylpropanenitrile

(14a): white solid, mp 106-108 °C; ^1H NMR (400 MHz, CDCl_3) δ 6.54 (s, 2H), 1.41 (s, 3H), 1.29 (s, 6H), 1.25 (s, 18H); ^{13}C NMR (100 MHz, CDCl_3), δ 185.6, 149.3, 140.7, 123.5, 42.7, 39.8, 35.1, 29.4, 22.9, 22.6; HRMS (ESI $^+$) m/z [M+H $^+$] calcd for $\text{C}_{19}\text{H}_{29}\text{NO}$: 288.2322, Found: 288.2317.

5. The Single Crystal X-ray Diffraction Study

The Single Crystal X-ray Diffraction Study of **3aa**



CCDC 2156275 (**3aa**) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre *via* www.ccdc.cam.ac.uk/data_request/cif.

Table S3 Crystal data and structure refinement for CCDC 2156275.

| Empirical formula | C ₂₀ H ₁₇ N ₃ O ₂ |
|-------------------------------------|---|
| Formula weight | 331.36 |
| Temperature/K | 293 (2) |
| Crystal system | monoclinic |
| Space group | P2 ₁ /c |
| a/Å | 9.5434 (4) |
| b/Å | 10.6963 (7) |
| c/Å | 16.8676 (6) |
| α/° | 90 |
| β/° | 101.643 (4) |
| γ/° | 90 |
| Volume/Å ³ | 1686.40 (13) |
| Z | 4 |
| ρ _{calc} g/cm ³ | 1.305 |
| μ/mm ⁻¹ | 0.696 |
| F(000) | 696.0 |
| Crystal size/mm ³ | 0.22 × 0.15 × 0.1 |
| Radiation | CuKα (λ = 1.54184) |
| 2Θ range for data collection/° | 9.462 to 134.158 |
| Index ranges | -11 ≤ h ≤ 11, -6 ≤ k ≤ 12, -17 ≤ l ≤ 20 |
| Reflections collected | 6134 |
| Independent reflections | 3002 [R _{int} = 0.0277, R _{sigma} = 0.0364] |
| Data/restraints/parameters | 3002/0/232 |
| Goodness-of-fit on F ² | 1.031 |


Final R indexes [$I \geq 2\sigma$ (I)]
Final R indexes [all data]
Largest diff. peak/hole / e Å⁻³


$$R_1 = 0.0444, wR_2 = 0.1194$$



$$R_1 = 0.0600, wR_2 = 0.1358$$

$$0.16/-0.21$$

6. Copies of ^1H , ^{13}C NMR Spectra for the Products












3ca


3ca




3da















3e a




























31a




—161.120
 —151.071
 —148.863
 —147.886
 —134.939
 —129.803
 —128.709
 —128.285
 —127.937
 —127.034
 —126.225
 —126.165
 —122.949
 —121.011
 —120.777
 —119.258
 —114.316












30a

























































7. HRMS (ESI $^+$) m/z [M+H $^+$] calcd for the Products























































8. Reference

- [1]. R. Shang, L. Ilies, E. Nakamura, J. Am. Chem. Soc. 2015, 137, 7660.